Albertsson-Wikland K
Acta Paediatr Scand Suppl. 1986;325:64-70. doi: 10.1111/j.1651-2227.1986.tb10367.x.
A study of 31 children with short stature was initiated in 1982. They received subcutaneous injections of pituitary hGH, 0.1 IU/kg/day; no adverse effects were seen and none of the patients acquired antibodies. Only the results of the first year are presented, as final height has not yet been attained. A high growth response was seen in 29 of the 31 children; they experienced an initial rise of IGF-1, IGF-2, alkaline phosphatase and procollagen III. The best response was obtained in the child with the lowest levels of endogenous pulsatile hGH secretion.
1982年开始了一项针对31名身材矮小儿童的研究。他们接受皮下注射垂体生长激素，剂量为0.1国际单位/千克/天；未观察到不良反应，且无患者产生抗体。由于尚未达到最终身高，仅呈现第一年的结果。31名儿童中有29名出现了高生长反应；他们的胰岛素样生长因子-1（IGF-1）、胰岛素样生长因子-2（IGF-2）、碱性磷酸酶和前胶原III水平最初有所上升。内源性脉冲式生长激素分泌水平最低的儿童获得了最佳反应。
